In this Trending News US episode, Jen, Mindy, and Ryan discuss recent newsworthy items, including the introduction of rebate credits by CVS to account for more biosimilars entering the market, as well as a recent ruling by a federal appeals court that drugmakers cannot restrict 340B program offerings from community and specialty pharmacies. Finally, we discuss a groundbreaking procedure in which a kidney from a CRISPR gene edited pig was transplanted into a human
Podcast Tags: healthcare, healthcare news, CVS health, PBMs, biosimilars, 340B, pharmacies, hospitals, providers, xenotransplantation, CRISPR, gene editing
Source Links:
Panel – Jen Burke, Mindy McGrath, Ryan Hummel
Research & Production – Anna Briccetti, Jen Burke
Recording & Editing – Mike Liberto, Rachel Skonecki
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.
In the last three years, Generative AI (GenAI) has moved from novelty to expectation. Across industries, teams are being asked, whether explicitly or
Read moreInizio Ignite brings together Research Partnership, Putnam, Vynamic, and STEM.
Read moreInsights from ASH® 2025 on hematology innovation, CAR-T, bispecifics, diagnostics, and how connected strategy supports real-world adoption.
Read more